Studies have shown that targeted small-molecule IBR2 can interfere with RAD51, accelerate the degradation of RAD51 protein, thus damage HR, induce apoptosis of breast cancer cells, and provide a new treatment of HER2-negative breast cancer (68). Here, ERBB2 is linked to breast carcinoma.